SLC29A1 and Huntington disease: Receptor binding assays showed T1-11 could activate adenosine 2A (A2AR) (IC50= 4.66 μM; Ki= 2.62μM; agonist) and A3 receptors (IC50= 0.11μM; Ki= 0.10μM; not significant in function), inhibit ENT1 (IC50= 1.57μM; Ki= 0.54μM; inhibitor), ameliorate motor degeneration in a mouse model of Huntington disease (HD) [11], and extend the lifespan of a mouse model of Niemann-Pick type C disease [11, 12].